A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A
Prospective, Observational , Multicenter Study of Effectiveness of Efanesoctocog Alfa on Long-term Joint Health in Patients With Hemophilia A
Sponsor: Sanofi
Listed as NCT05911763, this observational or N/A phase trial focuses on Hemophilia A and remains ongoing. Sponsored by Sanofi, it has been updated 11 times since 2023, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Nov 2025 — Present [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Sep 2025 — Nov 2025 [monthly]
Recruiting
-
Jun 2025 — Sep 2025 [monthly]
Recruiting
-
Apr 2025 — Jun 2025 [monthly]
Recruiting
-
Nov 2024 — Apr 2025 [monthly]
Recruiting
▶ Show 6 earlier versions
-
Sep 2024 — Nov 2024 [monthly]
Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting
-
Apr 2024 — Jul 2024 [monthly]
Recruiting
-
Oct 2023 — Apr 2024 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jul 2023 — Oct 2023 [monthly]
Not Yet Recruiting
First recorded
Jun 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .